Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling

Area of Science:

• Neuro-oncology
• Molecular pathology
• Cancer biology

Background:

• Gliosarcoma (GS) is a glioblastoma (GB) variant with mesenchymal differentiation, but its distinct pathological and molecular identity remains debated.
• Current treatment approaches for GS and GB are generally similar, despite potential underlying molecular differences.

Purpose of the Study:

• To investigate molecular differences between gliosarcoma (GS) and glioblastoma (GB) using comprehensive molecular profiling.
• To identify novel molecular associations that could elucidate the pathogenesis of GS compared to GB.

Main Methods:

• Retrospective analysis of molecular profiling data from 48 GS and 1229 GB cases.
• Utilized next-generation sequencing (NGS), copy number variation (CNV) analysis, and immunohistochemistry (IHC).
• Assessed 1153 molecular tests to identify statistically significant differences (p<0.1, Fisher's exact test).

Main Results:

• Identified 14 molecular tests with potentially meaningful associations between GS and GB.
• Observed significantly higher levels of immuno-evasion proteins (PD-1, PD-L1) in GS.
• Detected novel changes in glial tumors, including LYL1 copy number amplification and PTPN11 mutations, consistent with epithelial-to-mesenchymal transition (EMT).

Conclusions:

• Gliosarcoma exhibits distinct molecular characteristics suggestive of EMT compared to glioblastoma.
• Therapeutic strategies targeting immuno-evasion may hold greater promise for gliosarcoma treatment.